Entrada Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Entrada Therapeutics Inc 's ROA in the third quarter of 2026?
Entrada Therapeutics Inc recorded a cumulative net loss of $-5 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -1.63%.

However, within the Healthcare sector 101 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 728, from total ROA ranking in the second quarter of 2026 at 2983.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-35.36 %	-33.4 %	-31.03 %	-16.69 %	-13.82 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-5	34	34	-1	-67
Return On Assets (TTM)	-1.63 %	9.51 %	8.57 %	-0.21 %	-14.86 %
TRDA's Total Ranking	# 728	# 2983	# 3429	# 3403	# 696
Total Assets (TTM) in million	267	299	336	377	413
Seq. Total Assets Change	-10.71 %	-10.92 %	-11.09 %	-8.6 %	-8 %
Seq. Net Income Change	-	-	-	-	-

TRDA's 5 Years Annual ROA >> Back to TRDA Management Effectiveness >> Compare TRDA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 39
Sector	# 102
Overall	# 633

Return On Assets Statistics
High	Average	Low
83.12 %	4.09 %	-33.22 %
(Mar 31 2022)		(Dec 31 2022)

News about Entrada Therapeutics Inc Return on Assets ROA

Entrada Therapeutics Launches ELEVATE-45-201 Study, Pioneering Exon Skipping Strategies in Duchenne Muscular Dystrophy Treatment

In a significant advancement for the treatment of Duchenne Muscular Dystrophy (DMD), Entrada Therapeutics has received authorization from the United Kingdom s regulatory authorities to initiate the ELEVATE-45-201 study. This Phase 1/2 Multiple Ascending Dose clinical trial will assess ENTR-601-45, a promising investigational drug designed for individuals living with DMD who are amenable to exon 45 skipping. This authorization comes at a time of heightened urgency to discover effective therapeutic strategies for a condition that has long stymied conventional treatments.DMD is a devastating genetic disorder primarily affecting young males and characterized by relentless muscle degeneration and weakness. The underlying cause of DMD lies in mutations in the dystrophin gene, which results in the absence of dystrophin—a crucial protein that serves to protect muscle fibers from damage during contractions. Traditionally, this absence accelerates muscle deterioration, leading to significant functional impairments and a drastically reduced lifespan, with many patients experiencing loss of ambulation by their late teens and succumbing to cardiac and respiratory complications in early adulthood.

Financial Statements
Entrada Therapeutics Inc 's Assets	$ 267 million	TRDA's Balance sheet
Entrada Therapeutics Inc 's Income	$ -40 million	Quarterly TRDA's Income Statement
TRDA's Income by Division		See TRDA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-16.69 %	17.36 %	71.12 %	-26.25 %	-
Total Assets in million	377	453	386	226	306
Y / Y Net Income Change	-	2359.71 %	-	-	-
Net Income in million	-1	132	5	-95	-51
Annual Return On Assets	-0.24 %	29.17 %	1.39 %	-41.95 %	-16.73 %

TRDA's 5 Years Annual ROA >> Back to TRDA Management Effectiveness >> Compare TRDA ROA to its Competitors

More Return On Assets Ratios
TRDA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TRDA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TRDA's Competitors
Subscribers only: Roa for Entrada Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for TRDA's Customers

You may also want to know
TRDA's Roi	TRDA's Inventory Turnover Ratio	TRDA's Growth Rates	TRDA's Dividend Comparisons
	TRDA's Profitability Ratios	TRDA's Asset Turnover Ratio	TRDA's Dividend Growth
TRDA's Roe	TRDA's Valuation Ratios	TRDA's Financial Strength Ratios	TRDA's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-06T06:01:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.